Dina Schneider

Tasso Announces 2023 Growth, CE Mark for Tasso+® and Expanded Commercial, Clinical Partnerships

Tasso reported strong 2023 growth driven by expanding patient-centric, remote blood collection solutions and new commercial, clinical, and community collaborations. The company highlighted milestones such as CE Mark certification for the Tasso+® device and plans to further expand decentralized clinical trial and diagnostic capabilities in 2024.